CN117247431A - 一种具有dpp-iv抑制活性的苦荞肽及其应用 - Google Patents
一种具有dpp-iv抑制活性的苦荞肽及其应用 Download PDFInfo
- Publication number
- CN117247431A CN117247431A CN202311533246.0A CN202311533246A CN117247431A CN 117247431 A CN117247431 A CN 117247431A CN 202311533246 A CN202311533246 A CN 202311533246A CN 117247431 A CN117247431 A CN 117247431A
- Authority
- CN
- China
- Prior art keywords
- tartary buckwheat
- peptide
- dpp
- inhibition
- tartary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 244000130270 Fagopyrum tataricum Species 0.000 title claims abstract description 115
- 235000014693 Fagopyrum tataricum Nutrition 0.000 title claims abstract description 115
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 110
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 26
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 title claims abstract 12
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 title claims abstract 9
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 37
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 37
- 230000005764 inhibitory process Effects 0.000 claims abstract description 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 26
- 230000000694 effects Effects 0.000 claims abstract description 24
- 102000004190 Enzymes Human genes 0.000 claims abstract description 17
- 108090000790 Enzymes Proteins 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 238000000746 purification Methods 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 7
- 238000000926 separation method Methods 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 8
- 238000000108 ultra-filtration Methods 0.000 claims description 7
- 239000004365 Protease Substances 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 238000004811 liquid chromatography Methods 0.000 claims description 5
- 239000003208 petroleum Substances 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000010612 desalination reaction Methods 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 238000010979 pH adjustment Methods 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000011278 co-treatment Methods 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 235000013402 health food Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000003032 molecular docking Methods 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 230000003993 interaction Effects 0.000 abstract description 6
- 125000000539 amino acid group Chemical group 0.000 abstract description 4
- 238000004458 analytical method Methods 0.000 abstract description 4
- 230000002860 competitive effect Effects 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 4
- 239000001257 hydrogen Substances 0.000 abstract description 4
- 230000002209 hydrophobic effect Effects 0.000 abstract description 4
- 230000006961 mixed inhibition Effects 0.000 abstract description 4
- 230000036963 noncompetitive effect Effects 0.000 abstract description 4
- 238000000605 extraction Methods 0.000 abstract 1
- 238000010983 kinetics study Methods 0.000 abstract 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 62
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 62
- 229940088598 enzyme Drugs 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000287 crude extract Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 108091005658 Basic proteases Proteins 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- 108090000526 Papain Proteins 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- VBBFIBMVFSUUBP-MERQFXBCSA-N (2S)-1-(2-aminoacetyl)-N-(4-nitrophenyl)pyrrolidine-2-carboxamide hydrochloride Chemical compound Cl.NCC(=O)N1CCC[C@H]1C(=O)NC1=CC=C([N+]([O-])=O)C=C1 VBBFIBMVFSUUBP-MERQFXBCSA-N 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 108010007119 flavourzyme Proteins 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- -1 salt ions Chemical class 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 101000946377 Bos taurus Alpha-lactalbumin Proteins 0.000 description 1
- 240000006162 Chenopodium quinoa Species 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 241000277263 Salmo Species 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于食源性活性肽开发技术领域,具体涉及一种具有DPP‑IV抑制活性的苦荞肽及其应用。通过苦荞蛋白制备、酶解、提取、分离纯化、鉴定获得了两条具有DPP‑IV抑制活性的苦荞肽,分别是RLSIRPP(SEQ ID NO.2)和LHIVGPDK(SEQ ID NO.3)。分子对接分析苦荞肽与DPP‑IV酶的结果表明苦荞肽与DPP‑IV酶的氨基酸残基之间有11个氢键、6个疏水作用、2个静电结合、18个范德华力相互作用;酶抑制动力学研究表明苦荞肽抑制DPP‑IV酶为竞争性和非竞争性混合型抑制类型。本发明中的DPP‑IV苦荞抑制肽可用于以降血糖为目的的保健食品、药品的开发。
Description
技术领域
本发明属于食源性活性肽开发技术领域,特别涉及一种具有DPP-IV抑制活性的苦荞肽及其应用。
背景技术
二肽基肽酶Ⅳ(DPP-IV)是调控血糖的重要靶点。在人体内DPP-IV具有降解胰高糖素样肽-1(GLP-1)的作用,阻碍了GLP-1发挥降低血糖的活性,从而使血糖失去控制。因此,DPP-IV抑制剂的研发成为治疗Ⅱ型糖尿病的重要途径。来源于谷物蛋白的活性肽的调控血糖作用已被证实与DPP-IV酶抑制活性密切相关。
食源性DPP-IV抑制肽主要来源于动物、植物及乳制品。从沙丁鱼蛋白中鉴定出DPP-IV抑制肽DTMYDT的IC50为1.83 mg/mL;大西洋鲑鱼皮蛋白来源的DPP-IV抑制肽LDKVFR的IC50为128.71 μmol/L。而乳制品中筛选出的肽,均具有较高的DPP-IV抑制活性。从牛α-乳清蛋白中鉴定出DPP-IV抑制肽ILDKVGINY的IC50为1.0 mg/mL。特别是酪蛋白中的DPP-IV抑制肽活性最强的是IPI,其IC50在3.2-7.40 μmol/L。相比动物蛋白,植物蛋白来源更广,价格经济,生长周期短,且属于可再生能源,是食源性DPP-IV抑制肽的一种优质来源。
已有报道,藜麦蛋白筛选出的DPP-IV抑制肽混合物的IC50为0.23 mg/mL-0.98mg/mL,纯化出活性最强的HPF的IC50最低可达13.69 μg/mL;燕麦蛋白筛选出的DPP-IV抑肽混合物的IC50为0.68 mg/mL-0.99 mg/mL,纯化出活性最强的LQAFEPLR的IC50最低可达103.5 μmol/L。然而,苦荞蛋白源的多肽对DPP-IV抑制活性未知,其影响活性的分子量分布及活性序列也不清楚。本申请以苦荞粉为主要来源,筛选纯化出具有DPP-IV抑制活性的苦荞肽,RLSIRPP和LHIVGPDK;并通过对接分析证明苦荞肽与DPP-IV酶有7个氢键残基关联和4个疏水相互作用残基关联;此外通过酶抑制动力学分析,证明苦荞肽抑制DPP-IV酶为竞争性和非竞争性混合型抑制类型。
发明内容
针对现有技术的不足和实际需求,本发明的目的是为了获得具有DPP-IV抑制活性的苦荞肽,用于以降血糖为目的的保健食品、药品的开发。
本发明的目的是通过以下技术方案实现的:
本发明提供一种具有DPP-IV抑制活性的苦荞肽,所述多肽的氨基酸序列为:RLSIRPP,如SEQ ID NO.2所示。
本发明还提供一种具有DPP-IV抑制活性的苦荞肽,所述多肽的氨基酸序列为:LHIVGPDK,如SEQ ID NO.3所示。
本发明提供一种苦荞肽的制备方法,采用如下方法制备:
(1)苦荞蛋白制备:将苦荞粉和石油醚混合,获得脱脂苦荞粉,然后再通过pH调节、透析、除盐、干燥,获得苦荞蛋白;
(2)苦荞蛋白酶解:采用4%复合酶对pH7,2%苦荞蛋白进行酶解;
(3)苦荞肽复合物提取:将(2)反应后溶液煮沸,灭活蛋白酶,离心收集上清,获得苦荞肽粗提物;
(4)苦荞肽分离纯化:采用超滤和液相色谱分离纯化,然后结合Nano LC-MS/MS测序,确定苦荞肽组成。
所述苦荞肽为RLSIRPP和LHIVGPDK。
具体的制备方法为:
(1)苦荞蛋白(PO)制备:将苦荞粉与石油醚按1:5料液比混合,室温600 rpm搅拌1h,经减压抽滤并干燥后得脱脂苦荞粉,然后按照10%加入水中,调节pH至7-13,搅拌1 h,6000 rpm离心5 min得上清蛋白液。调节上清蛋白液pH至4.5,6000 rpm离心5 min,后收集PO沉淀。沉淀用水复溶,调节pH为7,经透析24 h,除去盐离子,再经干燥,获得PO。
(2)PO酶解:2%的PO溶液调整pH=7,充分搅拌1 h,煮沸15 min后与4%复合酶(中性酶、风味酶、木瓜蛋白酶、碱性蛋白酶、胃蛋白酶、胰蛋白酶)进行反应。各酶粉逐个加入前调整PO液至最佳酶反应温度和pH值。
(3)苦荞肽复合物提取物(PP):PO酶解液充分搅拌,煮沸10min灭活酶后,10000rpm离心10 min,收集水解物上清液为苦荞肽粗提物。
(4)苦荞肽分离纯化:根据苦荞肽组分大小利用超滤膜孔径分离,将苦荞肽粗提物用0.45 μM水膜过滤,冷冻离心(8000 rpm,4℃,30 min)后,将苦荞肽截留分离为>10 kDa,3-10 kDa、<3 kDa组分。采用Nano LC-MS/MS测序活性最高的苦荞纯化肽,并采用BLAST®工具明确苦荞多肽序列。
本发明还提供一种组合物,包含RLSIRPP和/或LHIVGPDK;所述组合物还包括稳定剂、乳化剂、调味剂。
本发明还提供一种苦荞肽在DPP-IV蛋白酶活性调控中的应用。
本发明还提供一种苦荞肽在制备预防或辅助治疗受益于DPP-IV抑制的疾病的药物或食品中的应用。
本发明还提供一种组合物在制备预防或辅助治疗受益于DPP-IV抑制的疾病的药物或食品中的应用,如RLSIRPP和LHIVGPDK苦荞肽按照不同比例调配组合。
本发明还提供上述苦荞肽在制备药品、保健食品和食品添加剂中的应用。
本发明相比现有技术的有益效果为:
(1)发现苦荞来源的新肽段,其中DPP-IV抑制活性最高的肽段序列为七肽RLSIRPP(SEQ ID NO.2)和八肽LHIVGPDK(SEQ ID NO.3),IC50分别为2.46 mM(2.06 mg/mL)、1.67mM(1.47 mg/mL)。
(2)通过分子对接方法分析,结果显示苦荞肽与DPP-IV酶的氨基酸残基之间有11个氢键、6个疏水作用、2个静电结合、18个范德华力相互作用。
(3)通过酶抑制动力学研究,表明苦荞肽抑制DPP-IV酶为竞争性和非竞争性混合型抑制类型。
(4)上述DPP-IV抑制肽可应用于以降血糖为目的的保健食品、药品的开发。
附图说明
图1 纯化前后苦荞肽组分DPP-IV抑制率;PO表示苦荞蛋白,PP表示苦荞肽复合物提取物;不同小写字母表示不同分子量组分间存在显著性差异(P<0.05)。
图2 液相色谱进一步纯化前后苦荞肽组分DPP-IV抑制率;不同字母表示各多肽纯化组分对DPP-IV抑制率有显著性差异(P<0.05)。
图3 苦荞肽二级质谱图。
图4 苦荞肽分子结构示意图。
图5 苦荞肽与DPP-IV互作的分子对接示意图。
图6 苦荞肽对DPP-IV抑制的Lineweaver-Burk双倒数图。
具体实施方式
以下将通过实施例对本发明进行详细描述。应当能够理解的是,以下实施例仅用于示例性地进一步详细解释和说明本发明的内容,而不用于限制本发明。
以下实施例中,苦荞粉为2022年四川省昭觉县收获的籽粒在环太公司加工制成的全粉;中性酶、风味酶、木瓜蛋白酶、碱性蛋白酶、胃蛋白酶、胰蛋白酶等购买自源叶生物公司;石油醚、三氟乙酸、乙腈、Tris-HCl缓冲液等实验中用到的化学试剂为常规试剂,可在国药集团化学试剂有限公司购买。
实施例1、制备DPP-IV抑制活性的苦荞肽
(1)苦荞蛋白(PO)制备:将苦荞粉与石油醚按1:5料液比混合,室温600 rpm搅拌1h,经减压抽滤并干燥后得脱脂苦荞粉,然后按照10%加入水中,调节pH至7-13,搅拌1 h,6000 rpm离心5 min得上清蛋白液。调节上清蛋白液pH至4.5,6000 rpm离心5 min,后收集PO沉淀。沉淀用水复溶,调节pH为7,经透析24 h,除去盐离子,再经干燥,获得PO。
(2)PO酶解:2%的PO溶液调整pH=7,充分搅拌1 h,煮沸15 min后与4%复合酶(中性酶、风味酶、木瓜蛋白酶、碱性蛋白酶、胃蛋白酶、胰蛋白酶)进行反应。各酶粉逐个加入前调整PO液至最佳酶反应温度和pH值。
(3)苦荞肽复合物提取物(PP):PO酶解液充分搅拌,煮沸10min灭活酶后,10000rpm离心10 min,收集水解物上清液为苦荞肽粗提物。
(4)苦荞肽分离纯化:根据苦荞肽组分大小利用超滤膜孔径分离,将苦荞肽粗提物用0.45 μM水膜过滤,冷冻离心(8000 rpm,4℃,30 min)后,将苦荞肽截留分离为>10 kDa,3-10 kDa、<3 kDa组分。DEAE-52离子柱分离和超滤分离的苦荞肽均取<3 kDa组分,然后进行DPP-Ⅳ抑制活性测定。
由图1结果发现,PO无DPP-IV抑制活性;与未超滤分离处理的PP相比,<3 kDa组分DPP-IV抑制率显著增加,从30.17%增加至40.04%,3-10 kDa和>10 kDa组分DPP-IV抑制活性显著低于PP的活性,这表明苦荞DPP-IV抑制肽聚集在分子量<3 kDa的组分中;超滤分离处理有效筛选出分子量更小、DPP-IV抑制活性更高的苦荞肽组分。
实施例2 苦荞肽的进一步纯化
将上述苦荞肽分离液中DPP-IV抑制率最高的<3 kDa的组分,采用液相色谱进一步纯化,筛选出活性更高的DPP-IV抑制肽,并明确其具体肽段的氨基酸序列。流动相A为0.1%三氟乙酸的超纯水,流动相B为0.1%三氟乙酸的乙腈,进样量50 μL,流速1 mL/min。采用梯度洗脱:流动相0 min,5 % B;5 min,10% B; 22 min,20% B,24 min,60% B;25 min,5% B;30 min,5% B。分别对收集的多肽进行DPP-IV抑制实验,比较各组分对DPP-IV的抑制活性。
由图2结果发现,液相色谱分离出6个峰,纯化的H1、H4、H5、H6对DPP-IV的抑制活性显著高于纯化前<3 kDa的混合组分,说明纯化能够筛选掉DPP-IV抑制活性较弱的苦荞肽组分。
采用Nano LC-MS/MS测序活性最高的H1苦荞纯化肽,并采用BLAST®工具明确苦荞多肽序列。分离出DPP-IV抑制活性最强的苦荞肽6个,各组分氨基酸序列及分子量如表1所示。质谱图如图3所示。值得注意的是分子量相近的3个八肽,对DPP-IV的抑制率却完全不同,SEQ ID NO. 3最高与SEQ ID NO. 5最低的活性相差4倍。其中,SEQ ID NO. 5八肽与分子量更小的六肽和分子量更大的十四肽的抑制率相近。这说明,分子量不是衡量苦荞肽DPP-IV抑制活性的唯一标准。
表1 DPP-IV抑制活性最高的苦荞肽段序列
注:序列中氨基酸缩写为:Q-谷氨酰胺(Gln);M-蛋氨酸(Met);P-脯氨酸(Pro);E-谷氨酸(Glu);K-赖氨酸(Lys);R-精氨酸(Arg);L-亮氨酸(Leu);S-丝氨酸(Ser);I-异亮氨酸(Ile);H-组氨酸(His);V-缬氨酸(Val);G-甘氨酸(Gly);D-天冬氨酸(Asp);N-天冬酰胺(Asn);T-苏氨酸(Thr);
实施例3 苦荞肽与DPP-IV酶的分析对接
采用分子对接方法,进一步对不同分子量的苦荞肽进行筛选,明确苦荞肽与DPP-IV的结合构象。DPP-IV酶(PDB代码:5J3J)的三维结构图从蛋白质数据库下载。苦荞多肽采用ChemDraw19.0软件绘制并进行结构优化。在对接程序之前,使用PyMOL 2.4软件(Schrodinger, LLC, New York, USA)从5J3J中除去配体和水,再进行后续对接。根据Lamarckian遗传算法采用AutoDock 4.2.6确定可能的苦荞肽-酶构象。DPP-IV酶的催化位点用作对接位点。最后,选取最低结合能模型为最优苦荞肽-酶结合方式,并通过PyMOL和Discovery Studio 4.5软件可视化并处理苦荞肽-酶构象。图4为RLSIRPP和LHIVGPDK苦荞肽的分子结构示意图。
由图5结果显示,经筛选苦荞肽与DPP-IV酶结合的蛋白质残基的球体< 7 Å时,苦荞肽与DPP-IV酶的Trp 157(碳氢键),Ser 158(碳氢键),Trp 305,Glu 361,Phe 364,Thr365,Glu 408,Leu 410,Lys 463,Ser 460(碳氢键),Phe 461 的11个氢键残基关联,以及与Trp 62(π-烷基),Trp 305(π-烷基),His 363(π-烷基),Lys 463(烷基),Pro159(烷基)和Pro 218(烷基)的6个疏水相互作用残基关联,此外,亦可通过静电结合与Glu 361,His 363(π-阳离子)氨基酸残基作用。其余的氨基酸残基Thr 304,Trp 216,Ala 306,Leu 366,Glu464,Thr411,Ala 465,Thr156,Ser106,Leu 60,Ile 107,Arg 61,Pro159,Ile 63,Pro109,Ala 409,Glu 361和Val 459主要通过范德华力与苦荞肽相互作用。
RLSIRPP(SEQ ID NO. 2)和LHIVGPDK(SEQ ID NO. 3)这2条苦荞肽的结合能最低,分别为-3.67和-3.12。2条肽段合成后进行DPP-IV抑制活性进行验证,RLSIRPP的IC50为2.46 mM(2.06 mg/mL),LHIVGPDK的IC50为1.67 mM(1.47 mg/mL),即结合能低的苦荞肽,其抑制DPP-IV酶的活性也较强。
实施例4 酶抑制动力学
酶抑制动力学是研究抑制剂对酶作用类型的主要手段。通过在同一DPP-IV酶浓度条件下,不同活性多肽浓度对不同Gly-Pro-pNA底物浓度的抑制效果来鉴别抑制类型。绘制出吸光度变化的倒数与底物浓度倒数的Lineweaver-Burk图,纵坐标截距即1/Vmax,横坐标截距为-1/Km。活性多肽浓度设定为IC50、IC50/2、0 mg/mL,Gly-Pro-pNA底物浓度设定为0.25、0.5、1.0、1.5、3.0 mmol/L(均为添加浓度)。初速度的测定采用30 min内吸光值的变化量来表示。
结果如图6所示,RLSIRPP和LHIVGPDK两个苦荞肽的三条直线相交于第二象限,且随着多肽浓度的增加,纵轴截距变大,横坐标截距变小,Vmax逐渐变小,Km逐渐变大,表明苦荞肽抑制DPP-IV酶为竞争性和非竞争性混合型抑制类型。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.一种具有DPP-IV抑制活性的苦荞肽,其特征在于,所述多肽的氨基酸序列为:RLSIRPP,如SEQ ID NO.2所示。
2.一种具有DPP-IV抑制活性的苦荞肽,其特征在于,所述多肽的氨基酸序列为:LHIVGPDK,如SEQ ID NO.3所示。
3.一种苦荞肽的制备方法,其特征在于,采用如下方法制备:
(1)苦荞蛋白制备:将苦荞粉和石油醚混合,获得脱脂苦荞粉,然后再通过pH调节、透析、除盐、干燥,获得苦荞蛋白;
(2)苦荞蛋白酶解:采用4%复合酶对pH7,2%苦荞蛋白进行酶解;
(3)苦荞肽复合物提取:将(2)反应后溶液煮沸,灭活蛋白酶,离心收集上清,获得苦荞肽粗提物;
(4)苦荞肽分离纯化:采用超滤和液相色谱分离纯化,然后结合Nano LC-MS/MS测序,确定苦荞肽组成。
4.如权利要求3所述的制备方法,其特征在于,所述苦荞肽为权利要求1和/或2所述的苦荞肽。
5.一种组合物,其特征在于,包含权利要求1和/或权利要求2所述的苦荞肽。
6.如权利要求5所述的组合物,其特征在于,还包括稳定剂、乳化剂、调味剂。
7.如权利要求1或2所述的苦荞肽在DPP-IV蛋白酶活性调控中的应用。
8.如权利要求1或2所述的苦荞肽在制备预防或辅助治疗受益于DPP-IV抑制的疾病的药物或食品中的应用。
9.如权利要求5的所述的组合物在制备预防或辅助治疗受益于DPP-IV抑制的疾病的药物或食品中的应用,其特征在于,如权利要求1和权利要求2所述的苦荞肽按照不同比例调配组合。
10.如权利要求1或2所述的苦荞肽、如权利要求3或4所述的制备方法制备的苦荞肽、如权利要求5或6所述的组合物在制备药品、保健食品和食品添加剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311533246.0A CN117247431B (zh) | 2023-11-17 | 2023-11-17 | 一种具有dpp-iv抑制活性的苦荞肽及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311533246.0A CN117247431B (zh) | 2023-11-17 | 2023-11-17 | 一种具有dpp-iv抑制活性的苦荞肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117247431A true CN117247431A (zh) | 2023-12-19 |
CN117247431B CN117247431B (zh) | 2024-01-30 |
Family
ID=89128032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311533246.0A Active CN117247431B (zh) | 2023-11-17 | 2023-11-17 | 一种具有dpp-iv抑制活性的苦荞肽及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117247431B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117264019A (zh) * | 2023-11-22 | 2023-12-22 | 中国农业大学 | 一种苦荞蛋白源dpp-iv抑制肽及其分离纯化方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012162503A (ja) * | 2011-02-09 | 2012-08-30 | Shinshu Univ | 発酵ソバ抽出物 |
CN107602663A (zh) * | 2015-03-17 | 2018-01-19 | 上海应用技术大学 | 一种苦荞麦活性肽及其应用 |
CN109336953A (zh) * | 2018-11-26 | 2019-02-15 | 贵州医科大学 | 一种苦荞抗氧化肽及其制备方法和应用 |
CN114686551A (zh) * | 2022-03-16 | 2022-07-01 | 江南大学 | 一种豌豆蛋白源dpp-iv抑制肽及其筛选方法 |
CN115010787A (zh) * | 2022-01-21 | 2022-09-06 | 昆明理工大学 | 一种苦荞活性肽及其制备方法和新用途 |
CN116479077A (zh) * | 2022-10-28 | 2023-07-25 | 江南大学 | 高活性苦荞清蛋白降血压肽的制备方法 |
-
2023
- 2023-11-17 CN CN202311533246.0A patent/CN117247431B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012162503A (ja) * | 2011-02-09 | 2012-08-30 | Shinshu Univ | 発酵ソバ抽出物 |
CN107602663A (zh) * | 2015-03-17 | 2018-01-19 | 上海应用技术大学 | 一种苦荞麦活性肽及其应用 |
CN109336953A (zh) * | 2018-11-26 | 2019-02-15 | 贵州医科大学 | 一种苦荞抗氧化肽及其制备方法和应用 |
CN115010787A (zh) * | 2022-01-21 | 2022-09-06 | 昆明理工大学 | 一种苦荞活性肽及其制备方法和新用途 |
CN114686551A (zh) * | 2022-03-16 | 2022-07-01 | 江南大学 | 一种豌豆蛋白源dpp-iv抑制肽及其筛选方法 |
CN116479077A (zh) * | 2022-10-28 | 2023-07-25 | 江南大学 | 高活性苦荞清蛋白降血压肽的制备方法 |
Non-Patent Citations (4)
Title |
---|
JIAJUN YANG等: "Antidiabetic activity of Tartary buckwheat protein-derived peptide AFYRW and its effects on protein glycosylation of pancreas in mice", AMINO ACIDS, vol. 55, no. 8, pages 1063 - 1071 * |
WEIJING WU等: "Anti-diabetic effects of the soluble dietary fiber from tartary buckwheat bran in diabetic mice and their potential mechanisms", FOOD NUTR RES., vol. 65, pages 4998 * |
仇菊等: "苦荞调控血糖功效及其在糖尿病人主食开发中的应用", 中国食品学报, vol. 21, no. 09, pages 352 - 365 * |
左婕等: "苦荞活性肽P3对链脲佐菌素诱导的糖尿病小鼠的改善作用研究", 食品研究与开发, vol. 43, no. 15, pages 48 - 54 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117264019A (zh) * | 2023-11-22 | 2023-12-22 | 中国农业大学 | 一种苦荞蛋白源dpp-iv抑制肽及其分离纯化方法 |
CN117264019B (zh) * | 2023-11-22 | 2024-02-09 | 中国农业大学 | 一种苦荞蛋白源dpp-iv抑制肽及其分离纯化方法 |
Also Published As
Publication number | Publication date |
---|---|
CN117247431B (zh) | 2024-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Forghani et al. | Purification and characterization of angiotensin converting enzyme-inhibitory peptides derived from Stichopus horrens: Stability study against the ACE and inhibition kinetics | |
Ling et al. | Preparation and identification of novel inhibitory angiotensin-I-converting enzyme peptides from tilapia skin gelatin hydrolysates: Inhibition kinetics and molecular docking | |
CN117247431B (zh) | 一种具有dpp-iv抑制活性的苦荞肽及其应用 | |
Rho et al. | Purification and identification of an angiotensin I-converting enzyme inhibitory peptide from fermented soybean extract | |
Rawendra et al. | A novel angiotensin converting enzyme inhibitory peptide derived from proteolytic digest of Chinese soft-shelled turtle egg white proteins | |
JP2013516427A (ja) | 大豆加工ストリームから単離される精製ボーマン・バークプロテアーゼインヒビタープロテイン | |
CN109293740B (zh) | 一种牡蛎来源的ace抑制及抗肿瘤活性肽 | |
KIM et al. | Novel angiotensin-I-converting enzyme inhibitory peptides derived from recombinant human αs1-casein expressed in Escherichia coli | |
CN111269290B (zh) | 一种鲟鱼抗炎肽的制备方法 | |
Mousavi et al. | Antidiabetic bio-peptides of soft and hard wheat glutens | |
AU591474B2 (en) | Serine protease inhibitors and methods for isolation of same | |
Welderufael et al. | Chemical characterisation and determination of sensory attributes of hydrolysates produced by enzymatic hydrolysis of whey proteins following a novel integrative process | |
Feng et al. | Overview of the preparation method, structure and function, and application of natural peptides and polypeptides | |
Shao et al. | Peptides isolated from black soybean synergistically inhibit the activity of angiotensin converting enzyme (ACE) | |
Szerszunowicz et al. | The use of UniProtKB/BIOPEP for the analysis of oat globulin physicochemical parameters and bioactivity. | |
AU2009254570B2 (en) | Anxiolytic composition containing alphas1-casein-derived peptides | |
CN113072621B (zh) | 一种牦牛骨降血压肽及其制备方法与应用 | |
JP2000229996A (ja) | オクタペプチド、アンギオテンシンi変換酵素阻害ペプチド及びその製造方法 | |
WO2002055546A1 (fr) | Inhibiteurs de l'enzyme de conversion de l'angiotensine | |
JPH04506800A (ja) | ソマトトロピン類似体 | |
JP5757555B2 (ja) | 新規酸性プロテアーゼ及びその用途 | |
JP2001261698A (ja) | アンジオテンシンi変換酵素阻害剤およびその製造法 | |
Wu et al. | Selection of goat β-casein derived ACE-inhibitory peptide SQPK and insights into its effect and regulatory mechanism on the function of endothelial cells | |
DE60033141T2 (de) | Verfahren zum entfernen von den n-terminalen alaninresten mit aeromonas aminopeptidase | |
Facchiano et al. | Modeling the 3D structure of wheat subtilisin/chymotrypsin inhibitor (WSCI). Probing the reactive site with two susceptible proteinases by time-course analysis and molecular dynamics simulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |